Bone drug tested to save knees after ACL injury – but trial stalls
NCT ID NCT05204836
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early study tested whether a single infusion of zoledronic acid, a drug used for osteoporosis, could improve bone health and slow joint damage after an ACL tear. Only 4 people were enrolled before the trial was terminated, so the results are very limited. The study aimed to see changes in bone structure and joint health over 6 to 18 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Zoledronic acid injection
- What this could lead to
- If this approach worked, it might help prevent long-term joint damage after ACL injuries.
- What could go wrong
- This was a very small, early-phase trial that was terminated early, so we have little data. The drug also has known side effects like bone pain and kidney issues.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANTERIOR CRUCIATE LIGAMENT INJURIES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Calgary
Calgary, Alberta, T2N 1N4, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple pill speed up knee replacement recovery?
- Can a 3D-Printed gadget speed up knee recovery?
- Saving the ligament: a trial tests whether repairing a torn ACL beats replacing it
- Which tendon graft helps female athletes recover best after ACL surgery?
- Nerve block showdown: which technique eases ACL surgery pain best?
- Which ACL graft gets young athletes back in the game faster?